Pegvisomant
Also known as: B2036, B2036-PEG, GH receptor antagonist, PEGvisomant, Somavert
Source Pegvisomant at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pegvisomant is a pegylated growth‑hormone (GH) analogue that acts as a GH‑receptor antagonist. It is approved for subcutaneous use in patients with acromegaly, typically when surgery does not achieve remission or when other medical therapies are insufficient. Guidelines and consensus updates place pegvisomant among the key pharmacologic options for controlling excess GH and IGF‑1 in this disorder.
Mechanism of Action
Pegvisomant is a modified GH molecule that binds to the GH receptor without activating it, thereby blocking endogenous GH from signaling. By occupying the receptor, it prevents the downstream JAK2‑STAT5 pathway that normally stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1). The resulting reduction in circulating IGF‑1 mediates its therapeutic effect in acromegaly.
What the Research Shows
Multiple expert reviews and guideline updates (Pituitary Society 2021; Expert Rev Endocrinol Metab 2025; Mayo Clin Proc 2022; Nat Rev Endocrinol 2025) describe pegvisomant as an established medical therapy for acromegaly, especially after transsphenoidal surgery fails to normalize IGF‑1. Consensus statements highlight its role in achieving biochemical control and note that it may be used as primary therapy in selected patients without mass effect. While these sources affirm its clinical utility, they also emphasize that prospective, controlled studies are still needed to refine patient selection and long‑term outcomes.
Reported Benefits
Guideline authors report that pegvisomant can normalize IGF‑1 levels in patients who remain biochemically active after surgery or who are unsuitable for somatostatin analogues. Consensus recommendations cite its effectiveness in improving biochemical control and, in some cases, clinical symptoms associated with excess GH. The subcutaneous formulation allows outpatient administration and flexibility in dosing adjustments.
Limitations of the Evidence
The cited literature relies largely on expert opinion and consensus rather than large randomized trials, indicating a need for more robust prospective data. Pegvisomant is not positioned as first‑line therapy and is generally reserved for patients with persistent disease, which may limit its applicability. Cost, need for daily injections, and the requirement for regular monitoring are also noted as practical challenges.
Safety Considerations
The abstracts note that pegvisomant is used clinically and is generally well tolerated, but detailed adverse‑event data are not provided. Guidelines recommend monitoring, reflecting the need for vigilance regarding potential liver‑enzyme changes and injection‑site reactions, as commonly described in the broader literature, though these specifics are not detailed in the cited sources.
How It Is Administered
Pegvisomant is formulated for subcutaneous injection, typically administered once daily. The pegylated structure prolongs its half‑life, allowing outpatient self‑administration after appropriate training.
Routes of Administration
Goals & Uses
- Combination therapy with somatostatin analogsEndocrine / Combination TherapyModerate
- Normalization of IGF-1 levels in acromegalyEndocrine / MetabolicHigh
- Management of acromegaly in patients not candidates for surgeryMedical ManagementHigh
- Symptom control in acromegaly (headache, soft tissue swelling, diaphoresis)Symptomatic ReliefHigh
- Acromegaly controlEndocrinologyHigh
Contraindications
- Significant hepatic impairment or active liver diseaseHepaticHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to pegvisomant or any excipientAllergy / ImmunologicHigh
- Rapidly growing pituitary tumor at risk for chiasmal compressionOncologic / NeurologicHigh
Adverse Effects
- Elevated liver transaminases (hepatotoxicity)HepaticUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Pituitary tumor growthOncologic / EndocrineUncommon
- Fatigue and dizzinessGeneral / NeurologicCommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Hyperglycemia or altered glucose metabolismMetabolic / EndocrineUncommon
Drug Interactions
- Somatostatin analogs (octreotide, lanreotide)Low
- Cytochrome P450 inducersModerate
- Insulin / Oral antidiabetic agentsModerate
- OpioidsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeAbsolute
- Patients with diabetes mellitusMetabolicRelative
- Pregnant womenReproductiveAbsolute
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: AcromegalyEMA approval 2004
- United StatesApprovedApproved: Acromegaly in adultsFDA approval 2003
- United KingdomApprovedApproved: AcromegalyMHRA approved
FDA approved (2003) for acromegaly; EMA and MHRA approvals followed. Indicated for adults only; not recommended in pregnancy.
Evidence & Sources
- Journal ArticleModerateFleseriu M, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateFreda PU2025-01-01T00:00:00.000000Z
- Journal ArticleModerateMolitch ME2017-01-01T00:00:00.000000Z
- Journal ArticleModerateErshadinia N, Tritos NA2022-01-01T00:00:00.000000Z
- Journal ArticleModerateMelmed S, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is pegvisomant used to treat?
Pegvisomant is approved for the treatment of acromegaly, a disorder of excess growth hormone, especially when surgery or other medicines have not fully controlled the disease.
How does pegvisomant work?
It binds to the growth‑hormone receptor without activating it, blocking the natural hormone’s signal and thereby lowering the production of IGF‑1, the mediator of acromegaly’s effects.
Is pegvisomant a first‑line therapy?
Guidelines place it after transsphenoidal surgery or when other drugs (such as somatostatin analogues) are inadequate; it is not generally used as the initial treatment.
How is pegvisomant given?
The drug is supplied as a subcutaneous injection that patients can self‑administer, usually once daily.
What are the main safety considerations?
While considered well tolerated, clinicians monitor liver enzymes and injection‑site reactions, and adjust dosing based on IGF‑1 levels and patient response.
What is Pegvisomant?
Pegvisomant is a pegylated growth‑hormone (GH) analogue that acts as a GH‑receptor antagonist. It is approved for subcutaneous use in patients with acromegaly, typically when surgery does not achieve remission or when other medical therapies are insufficient. Guidelines and consensus updates place pegvisomant among the key pharmacologic options for controlling excess GH and IGF‑1 in this disorder.
What is Pegvisomant used for?
Pegvisomant is educationally associated with: Combination therapy with somatostatin analogs, Normalization of IGF-1 levels in acromegaly, Management of acromegaly in patients not candidates for surgery, Symptom control in acromegaly (headache, soft tissue swelling, diaphoresis), Acromegaly control. Educational only — not medical advice.
How is Pegvisomant administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Pegvisomant?
Reported adverse effects include: Elevated liver transaminases (hepatotoxicity), Injection site reactions, Headache, Pituitary tumor growth, Fatigue and dizziness, Elevated liver enzymes, Hyperglycemia or altered glucose metabolism. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pegvisomant?
Recorded contraindications: Significant hepatic impairment or active liver disease, Severe hepatic impairment, Pregnancy, Hypersensitivity to pegvisomant or any excipient, Rapidly growing pituitary tumor at risk for chiasmal compression. Consult a qualified clinician before use.